Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2-4 classes of oral preventive treatment: A post-hoc analysis of the ELEVATE trial

Authors
Category Primary study
Conference17th European Headache Congress (EHC)
Year 2024
This article has no abstract
Epistemonikos ID: 24598224fab6601c753d77780c58c54ce962131e
First added on: Jan 31, 2026